Monitoring the safe and effective use of medicines has now been an essential part of public health policy for several decades. New advances in technology (e.g., ICH E2B for the electronic exchange of case reports) over the past 20 years coupled with progressive legislation have been a catalyst for an explosion in safety data over this period.
Since the World Health Organization (WHO) declared the Covid-19 pandemic in March 2020, the rate of reporting of safety data has been unprecedented
Read More
GlaxoSmithKline
PathAI and GlaxoSmithKline Partner to Accelerate Research and Drug Development
What You Should Know:
- PathAI and GSK announced a multi-year strategic artificial intelligence (AI) partnership today with a focus on accelerating research and- building drug development programs in oncology and non-alcoholic steatohepatitis (NASH).
- As part of the partnership, GSK will leverage both PathAI’s expertise and models to advance GSK’s proprietary AI models and focus on designing better models to deliver improved treatment options for patients with cancer
Read More
Propeller to Connect AstraZeneca’s Inhaler Symbicort Users to Propeller Platform
What You Should Know:
Propeller Health has been awarded FDA 510(k) clearance to
connect patients using AstraZeneca’s Symbicort Inhaler to Propeller, enhancing medication
coverage and respiratory digital health.
The sensor for Symbicort, a controller medication for
asthma and COPD, was developed in partnership with AstraZeneca. With this new
medication on our roster, Propeller now connects to 90 percent of the inhaled
medications for asthma and COPD on the U.S. market.
Propeller
Read More
Cara Care Nabs $7M to Expand Digital Therapuetic App for Digestive Diseases
Berlin, Germany-based digital health company Cara Care, announced today that it has secured $7 million in Series A funding led by Johnson & Johnson Innovation – JJDC, Inc. (JJDC) and Barcelona-based VC firm Asabys Partners with participation from existing investor Atlantic Labs. Cara Care was part of the Microsoft Accelerator and winner of the GlaxoSmithKline Transforming the Future of Self-Care Challenge in the category “Digital Health Technologies.” Cara Care has raised more than $9
Read More
HealthQuest Capital Closes $440M Fund to Invest in Innovative Growth-Stage Companies
HealthQuest Capital, a Silicon Valley-based growth capital firm has closed a $440 million fund to invest growth-stage companies delivering innovation across all sectors of the healthcare industry to improve patient outcomes, enhance efficiency and reduce costs. Fund III was oversubscribed and closed at a hard cap. Target markets for Fund III include growth- and commercial-stage companies focusing on medical technologies, diagnostics, digital health, and innovative services.HealthQuest Capital
Read More
GlaxoSmithKline and Pfizer Form New Consumer Health Joint Venture
GlaxoSmithKline and Pfizer Inc to form new world-leading Consumer Healthcare Joint Venture provides a unique opportunity to accelerate GSK’s strategy and create substantial value for shareholders. GlaxoSmithKline has reached an agreement with Pfizer Inc to combine their consumer health businesses into a consumer health Joint Venture, with combined sales of approximately $12.7B. As part of the agreement, GSK will have a majority controlling equity interest of 68% and Pfizer will have an equity
Read More
GSK Acquires Novartis’ Consumer Healthcare Business for $13B
GlaxoSmithKline (GSK) has reached an agreement to acquire Novartis’ consumer healthcare joint venture for $13 billion. The acquisition will enable GSK’s shareholders to capture the full value of GSK’s Consumer Healthcare growth and is well positioned to deliver sales growth, operating margin improvements and attractive returns.Upon terms of the agreement, India remains a priority market for GSK investment and growth. The Consumer Healthcare business will continue to invest in growth
Read More
Propeller Health Expands Partnership with GlaxoSmithKline to Improve Management of Asthma and COPD
Propeller Health, a digital health company developing solutions respiratory medicine has announced the expansion of its 2015 collaboration with GlaxoSmithKline (GSK). As part of the expanded partnership, both companies will undertake commercial activities using the Propeller clip-on sensor and software platform for use with GSK’s ELLIPTA Inhaler. The companies will continue ongoing research and development efforts to collect evidence from the Propeller clip-on sensor and software platform used
Read More
Verily, GlaxoSmithKline Partner to Develop Bioelectronic Medicines
Alphabet company Verily (formerly Google Life Sciences) is teaming up with pharmaceutical firm GlaxoSmithKline to develop bioelectronic medicines. The new company, Galvani Bioelectronics headquartered in the UK aims to research, develop and commercialize implantable, miniature devices which could potentially treat illnesses such as arthritis, diabetes and asthma. As part of the agreement, GSK will hold 55% equity interest and Verily will hold 45% owned by Verily, and receive up to $712M funding
Read More
